公开(公告)号：US20250002963A1

公开(公告)日：2025-01-02

申请号：US18708869

申请日：2022-11-16

Applicant: TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES ,  NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

Inventor： Kazuma TOMIZUKA ,  Narumi UNO ,  Yasuhiro KAZUKI

IPC: C12P21/00 ,  C12N15/85

Abstract: A promoter activation sequence that allows for stable and efficient expression of a DNA of interest in a mammalian cell is provided. The promoter activation sequence has a nucleotide sequence represented by SEQ ID NO: 1, or a nucleotide sequence of 850 or more in a nucleotide sequence having 85% or higher sequence identity thereto. Also disclosed are an expression vector having the promoter activation sequence, a promoter, and a DNA of interest, a mammalian cell and a mammal including the expression vector.

公开(公告)号：US20210115440A1

公开(公告)日：2021-04-22

申请号：US16629511

申请日：2018-07-11

Applicant: TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES

Inventor： Takanori KANAZAWA ,  Yuuki TAKASHIMA ,  Hisako IBARAKI ,  Shunsuke SHIRAISHI ,  Ei NAKATA ,  Yusuke IRIYAMA ,  Keiichiro OTSUKA

IPC: C12N15/113 ,  A61K31/7105 ,  A61K31/713 ,  A61K9/14 ,  A61K9/107 ,  A61K47/34 ,  A61K47/42

Abstract: This is to provide a composition for delivering a nucleic acid and a nucleic acid-containing composition which ensure stability of a nucleic acid drug, have a high intracellular introduction rate, can efficiently express the function of a nucleic acid drug, and have low cytotoxicity.
Disclosed is a composition for delivering a nucleic acid and a nucleic acid-containing composition each comprises a block copolymer in which a polyethylene glycol segment and a hydrophobic polyester segment are linked, and a peptide having 4 to 30 residues containing at least one selected from the group consisting of arginine and lysine.

公开(公告)号：US20170218451A1

公开(公告)日：2017-08-03

申请号：US15486788

申请日：2017-04-13

Applicant: HIROTAKA MATSUO ,  NARIYOSHI SHINOMIYA ,  TAKAHIRO NAKAMURA ,  THE UNIVERSITY OF TOKYO ,  TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES

Inventor： HIROTAKA MATSUO ,  Nariyoshi Shinomiya ,  Takahiro Nakamura ,  Tappei Takada ,  Hiroshi Suzuki ,  Yuki Ikebuchi ,  Kousei Ito ,  Kimiyoshi Ichida

IPC: C12Q1/68 ,  A61K38/17

CPC classification number: C12Q1/6883 ,  A61K38/177 ,  C07K14/705 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/566 ,  G01N33/6893 ,  G01N2800/24 ,  G01N2800/32 ,  G01N2800/34

Abstract: Methods of treating, or at least inhibiting the onset of, urate transport failure are provided. The methods can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.

公开(公告)号：US20220226479A1

公开(公告)日：2022-07-21

申请号：US17442797

申请日：2020-03-19

Applicant: University of Tsukuba ,  Tokyo University of Pharmacy and Life Sciences

Inventor： Takeo USUI ,  Yoko NAGUMO ,  Minagi MUKAIYAMA ,  Yoshio HAYASHI ,  Atsuhiko TANIGUCHI ,  Chihiro UCHIYAMA

IPC: A61K47/42

Abstract: There is provided technology for promoting permeation of a substance into a cell layer. Provided is a cell layer permeation promoter comprising a compound represented by general formula (1). Also provided is a composition for facilitating drug absorption that contains the cell layer permeation promoter, said composition being for facilitating absorption of a drug into a living body. Also provided is a pharmaceutical composition that contains the cell layer permeation promoter and furthermore contains a drug to be absorbed into a living body.

公开(公告)号：US11345914B2

公开(公告)日：2022-05-31

申请号：US16629511

申请日：2018-07-11

Applicant: TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES

Inventor： Takanori Kanazawa ,  Yuuki Takashima ,  Hisako Ibaraki ,  Shunsuke Shiraishi ,  Ei Nakata ,  Yusuke Iriyama ,  Keiichiro Otsuka

IPC: C07H21/04 ,  C12N15/113 ,  A61K9/107 ,  A61K9/14 ,  A61K31/7105 ,  A61K31/713 ,  A61K47/34 ,  A61K47/42

Abstract: This is to provide a composition for delivering a nucleic acid and a nucleic acid-containing composition which ensure stability of a nucleic acid drug, have a high intracellular introduction rate, can efficiently express the function of a nucleic acid drug, and have low cytotoxicity.
Disclosed is a composition for delivering a nucleic acid and a nucleic acid-containing composition each comprises a block copolymer in which a polyethylene glycol segment and a hydrophobic polyester segment are linked, and a peptide having 4 to 30 residues containing at least one selected from the group consisting of arginine and lysine.

公开(公告)号：US20230127046A1

公开(公告)日：2023-04-27

申请号：US17756275

申请日：2020-11-26

Applicant: RIKEN ,  TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES ,  MICROBIAL CHEMISTRY RESEARCH FOUNDATION

Inventor： Tatsunobu SUMIYA ,  Yosuke NISHIGAYA ,  Ryosuke NAMIE ,  Noriaki HASHIMOTO ,  Akihiro ITO ,  Fumiyuki SHIRAI ,  Ko KIKUZATO ,  Minoru YOSHIDA

IPC: C07D209/42 ,  C07D401/12 ,  C07D403/12 ,  C07D417/14 ,  C07D471/04

Abstract: A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, β-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).

公开(公告)号：US20150080257A1

公开(公告)日：2015-03-19

申请号：US14542633

申请日：2014-11-16

Applicant: HIROTAKA MATSUO ,  NARIYOSHI SHINOMIYA ,  TAKAHIRO NAKAMURA ,  THE UNIVERSITY OF TOKYO ,  TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES

Inventor： HIROTAKA MATSUO ,  Nariyoshi Shinomiya ,  Takahiro Nakamura ,  Tappei Takada ,  Hiroshi Suzuki ,  Yuki Ikebuchi ,  Kousei Ito ,  Kimiyoshi Ichida

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K38/177 ,  C07K14/705 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/566 ,  G01N33/6893 ,  G01N2800/24 ,  G01N2800/32 ,  G01N2800/34

Abstract: A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F2085, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.

Abstract translation: 提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。 该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。 当受试者具有V12M，R113X，Q126X，Q141K，F2085，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够 诱导尿酸盐运输失败，或归因于该失败的状态或疾病。 当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化， 所述变异与其他SNP的连锁不平衡有关。